

***Listeria monocytogenes* CadC regulates cadmium efflux and fine-tunes lipoprotein localization  
to escape the host immune response and promote infection**

Rita Pombinho<sup>1,2,3,#</sup>, Ana Camejo<sup>1,2,3,#</sup>, Ana Vieira<sup>1,2</sup>, Olga Reis<sup>1,2,3</sup>, Filipe Carvalho<sup>1,2,3</sup>, Maria Teresa Almeida<sup>1,2,3</sup>,  
Jorge Campos Pinheiro<sup>1,2,3</sup>, Sandra Sousa<sup>1,2</sup>, Didier Cabanes<sup>1,2,\*</sup>

<sup>1</sup> Instituto de Investigação e Inovação em Saúde – i3S, Universidade do Porto, Porto, Portugal

<sup>2</sup> Group of Molecular Microbiology, Instituto de Biologia Molecular e Celular - IBMC, Porto, Portugal

<sup>3</sup> Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal

# Equally contributed to this work

\* Corresponding author: [didier@ibmc.up.pt](mailto:didier@ibmc.up.pt)

Running title: *Listeria* CadC fine-tunes lipoprotein release

## Footnote

Conflict of interest: No conflict of interest

### Funding information:

This work was supported for the D.C. lab by national funds through FCT - Fundação para a Ciência e a Tecnologia/MEC - Ministério da Educação e Ciência and co-funded by FEDER funds within the partnership agreement PT2020 related with the research unit number 4293, and within the research project Infect-ERA/0001/2013 PROANTILIS. A.C., R.P., O.R., F.C., M.T.A. and J.C.P. were supported by doctoral fellowships from FCT (SFRH/BD/29314/2006, SFRH/BD/89542/2012, SFRH/BD/28185/2006, SFRH/BD/61825/2009, SFRH/BD/43352/2008 and SFRH/BD/86871/2012) and SS was supported by FCT Investigator program (COMPETE, POPH, and FCT).

### Corresponding author:

Didier cabanes  
IBMC - Instituto de Biologia Molecular e Celular, Group of Molecular Microbiology  
Rua do Campo Rua Alfredo Allen, 208  
4200-135 Porto  
Portugal  
Tel: +351 220 408 800 Ext. 6099  
e-mail: didier@ibmc.up.pt

## ABSTRACT

*Listeria monocytogenes* (*Lm*) is a major intracellular human foodborne bacterial pathogen. We previously revealed *Lm-cadC* as highly expressed during mouse infection. Here we show that *Lm*-CadC is a sequence-specific, DNA-binding and cadmium-dependent regulator of CadA, an efflux pump conferring cadmium resistance. CadC, but not CadA, is required for *Lm* infection *in vivo*. Interestingly, CadC also directly represses *lspB*, a gene encoding a lipoprotein signal peptidase whose expression appears detrimental for infection. *lspB* overexpression promotes the release of the LpeA lipoprotein to the extracellular medium, inducing TNF- $\alpha$  and IL-6 expression, thus impairing *Lm* survival in macrophages. We propose that *Lm* uses CadC to repress *lspB* expression during infection to avoid LpeA exposure to the host immune system, diminishing inflammatory cytokine expression and promoting intramacrophage survival and virulence. CadC appears as the first metal efflux pump regulator repurposed during infection to fine-tune lipoprotein processing and host responses.

**Word count: 145**

**Keywords:** *Listeria*/virulence factor; CadAC; Gram-positive; host-response; pathogen

62    **BACKGROUND**

63    Despite their toxicity at high concentration, some heavy metals are required as cofactors for enzymatic reactions  
64    or as structural components of bacterial proteins. Therefore, their intracellular concentration needs to be finely  
65    tuned to maintain metal homeostasis. Efflux pumps are usually substrate-specific and control intracellular metal  
66    concentrations conferring heavy metal resistance [1, 2]. In its ionized form cadmium is toxic for many organisms,  
67    including bacteria. Erosion, forest fires and volcanic eruptions are natural sources of cadmium which is dispersed  
68    into air, water, soils and foodstuffs. Cadmium resistance systems are commonly composed by a metal-responsive  
69    transcriptional repressor (CadC) belonging to the ArsR-SmtB family [3-5], and a P1-type ATPase (CadA) that  
70    extrudes heavy metals from the cell [6].

71    *Listeria monocytogenes* is a major intracellular foodborne bacterial pathogen causing listeriosis, a systemic  
72    infection in humans [7]. Among zoonotic diseases under EU-surveillance, listeriosis is the most severe with 99.1%  
73    of the cases hospitalized and a case fatality rate of 15.6% [8]. Listeriosis is clinically characterized by septicemia  
74    and dissemination to the nervous system and fetal-placental unit [9]. As a foodborne pathogen, *L. monocytogenes*  
75    has the capacity to colonize various niches, ranging from inert and organic matrixes to the intestinal lumen where  
76    it competes with resident microbiota, translocates across the epithelium, multiplies in phagocytic and non-  
77    phagocytic cells, disseminates *via* the blood and evades the immune response [7]. A functional CadAC system  
78    was previously identified in *L. monocytogenes* Lm74 on the Tn5422 transposable element harbored by the pLm74  
79    plasmid [10, 11], and was shown to be induced by and to confer resistance to cadmium [11]. We previously  
80    showed that, in *L. monocytogenes* EGDe (*Lm*), *cadC* is highly expressed during infection and required for *Lm*  
81    virulence [12].

82    Here we characterize the *Lm* cadmium resistance system and discover an unexpected role of CadC in bacterial  
83    pathogenicity.

84

85

86

## 87 **METHODS**

### 88 **Bacteria and cells**

89 *Lm* (ATCC-BAA-679) [13] were grown in BHI (BD-Difco) at 37°C with erythromycin (5 µg/ml), chloramphenicol (7  
90 µg/ml). *Escherichia coli* were grown in LB at 37°C with ampicillin (100 µg/ml), erythromycin (300 µg/ml),  
91 kanamycin (30 µg/ml). RAW-264.7 (ATCC-TIB-71) were cultured in DMEM 10% FBS (Lonza), BMDM in DMEM 10  
92 mM HEPES, 10% FBS and 10% L929-conditioned medium at 37°C, 5% CO<sub>2</sub>.

93 Deletions ( $\Delta cadA$ ,  $\Delta cadC$ ,  $\Delta cadAC$ ,  $\Delta lspB$ ,  $\Delta cadC\Delta lspB$ ), insertion ( $\Delta peA$ ) and complementation  
94 ( $\Delta cadC + cadC$ ) were performed as described [14, 15]. Overexpression (WT+*lspB*) was performed using pMK4-  
95 vector [16] carrying the strong constitutive P<sub>prot</sub>-promoter [17, 18]. Primers are listed Tab.S1. Constructs were  
96 confirmed by sequencing.

### 97 **Toxicity assays**

98 Cadmium challenge: 1/100-diluted overnight cultures were challenged after 210 min with 384 µM CdCl<sub>2</sub>. Growth  
99 (OD<sub>600</sub>) was measured every 45 min. Disk diffusion assays: plated bacterial lawns were overlaid with 6-mm paper-  
100 disk soaked with 10 µl of metal salt solution (100 mM). Growth inhibition zone diameter was measured after  
101 overnight incubation at 37°C. MICs: 96-wells microtiter plates containing BHI/metal-salt solutions (100/100 µl)  
102 were inoculated with 1 µl of overnight cultures. Growth was assessed (OD<sub>600</sub>) after 24h incubation at 37°C.

### 103 **Inductively coupled plasma mass spectrometry (ICP-MS)**

104 Bacterial cultures (OD<sub>600</sub>=0.6) were supplemented with 384 µM CdCl<sub>2</sub> 15 min, centrifuged, PBS-washed and  
105 lyophilized. Dried samples were digested with HNO<sub>3</sub>, suspended in 4N HNO<sub>3</sub>, diluted in water and analyzed by  
106 ICP-MS.

### 107 **Proteins**

108 *cadC* was cloned into pET28b, sequenced, and transformed in *E. coli* BL21(DE3). CadC-His<sub>6</sub> production was  
109 induced with 0.1mM IPTG at 37°C 3h. Cells were re-suspended, sonicated, cleared by centrifugation and soluble  
110 fraction purified by Ni-NTA-agarose chromatography (QIAGEN).

111 Lipoproteins were recovered by Triton X-114 phase-partitioning method [19] and culture supernatant proteins by  
112 TCA precipitation [20].

113 SDS-PAGE protein bands were excised, reduced with DTT, alkylated with iodoacetamide and in-gel digested with  
114 trypsin. Peptide identification was performed by MALDI TOF/TOF mass spectrometry [21].

#### 115 **Electrophoretic mobility shift assays (EMSAs)**

116 CadC-DNA binding assays were performed in 50 mM Tris-HCl pH7.4, 6 mM MgCl<sub>2</sub>, 100 mM NaCl, 50 mM KCl,  
117 100 ng DNA and purified CadC/GFP. After 20 min at RT samples were resolved in 6% polyacrylamide gel and  
118 visualized by DNA staining.

#### 119 **ChIP-qPCR**

120 Chromatin immunoprecipitation (ChIP) were performed as described [22] using anti-CadC polyclonal rabbit  
121 serum generated through CadC-His<sub>6</sub> as described [15]. 1-10 ng of ChIP Purified DNA (NZYGelpure) was  
122 analyzed by qPCR.

#### 123 **Macrophage infection**

124 Bone marrow cells were collected from C57BL/6 mouse femurs and differentiated 10 days. *Lm* (OD<sub>600</sub>=0.8) were  
125 added to BMDM or RAW at MOI 10 for 20/30 min. Macrophages were treated 10 min/4h30 with 20 µg/ml  
126 gentamicin, washed, lysed (0.1% Triton X-100) and intracellular bacteria enumerated by plating.

#### 127 **Transmission electron microscopy**

128 *Lm* (OD<sub>600</sub>=0.8) were fixed 1h at RT (4% paraformaldehyde, 2.5% glutaraldehyde, 0.1 M sodium-cacodylate,  
129 pH7.2), stained 2h with 1% osmium tetroxide and compacted in 30% BSA. Bacterial pellets were fixed overnight  
130 in 1% glutaraldehyde, dehydrated in ethanol and embedded in Epon-812. Ultrathin sections (40-50 nm) were  
131 placed on 400-mesh copper grids and visualized (Jeol JEM-1400).

#### 132 **RNA techniques**

133 RNAs were extracted from *Lm* (OD<sub>600</sub>=0.8) and RAW (5h p.i.), treated (TURBO-DNA-free, Ambion), quality-  
134 checked (Experion, Bio-Rad-Laboratories), reverse-transcribed (iScript, Bio-Rad-Laboratories) and analyzed by

135 qRT-PCR as described [12]. Gene expression data were analyzed by comparative Ct method [23], normalized to  
136 relative reference gene expression (*Lm* 16S rRNA or *Mus musculus* *hprt1*).

### 137 **Mouse infections**

138 Intravenous and oral inoculations were performed as described [24] (n=5). Animal procedures were in agreement  
139 with European Commission (directive 2010/63/EU) and Portuguese (Decreto-Lei 113/2013) guidelines, approved  
140 by IBMC Ethics Committee and Direcção Geral Veterinária (license PTDC/SAU-MIC/111581/2009).

### 141 **ELISA**

142 Cytokine levels released into infected RAW supernatant were measured using murine ELISA kit (eBioscience).

### 143 **Statistics**

144 Statistics were performed with Prism (GraphPad), using unpaired two-tailed Student's *t*-test to compare means of  
145 two groups, and one-way ANOVA with Tukey's post-hoc test for pairwise comparison of means from more than  
146 two groups, or with Dunnett's post-hoc test for comparison of means relative to the mean of a control group.

147

## 148 **RESULTS**

### 149 ***L. monocytogenes* chromosomally encodes a cadmium efflux system expressed in the presence of** 150 **cadmium and independently of PrfA**

151 *Lm-cadAC* encode proteins with high level of identity to CadAC cadmium efflux systems from several species  
152 (Fig.1AB, S1A). *Lm-CadC* displays classical DNA-binding helix-turn-helix motif and type-1 metal-binding site  
153 composed of four critical cysteines [25] (Fig.1A). The predicted *Lm-CadC* structure is close to *Staphylococcus*  
154 *aureus* (Sa) CadC (Fig.S1B). However, *Lm-CadC* lacks the type-2 metal-binding site present in Sa-CadC but  
155 dispensable for metal binding [26] (Fig.1A). *Lm-CadA* exhibits metal-binding domain and motifs conserved in P1-  
156 type ATPases, and is predicted to be a membrane protein with 8 transmembrane domains (Fig.S1C) [27].  
157 Whereas harbored by plasmids in different *Listeria* strains [10, 11, 28], *cadA* and *cadC* are located on the *Lm*  
158 chromosome. *Lm-cadA* is found downstream of *cadC*, with an oppositely oriented gene in between (*lspB*)  
159 encoding a putative lipoprotein signal peptidase type-II [29, 30] (Fig.1B). *cadA-lspB-cadC* are flanked by an

160 integrase-encoding gene (*lmo1097*) and 12 Tn916-like genes (*lmo1103-lmo1114*). The average GC content  
161 percentage (32%) of the *lmo1097-lmo1102* locus is notably lower than that of surrounding regions (39-43%)  
162 (Fig.1B).

163 We first analyzed whether *cadA*, *lspB* and *cadC* are transcribed from a single promoter. Whereas in presence of  
164 cadmium (Cd), independent transcripts were detected for the three genes, no co-transcript was observed (Fig.1C),  
165 indicating that in the conditions tested there is no *cadA-lspB-cadC* co-transcription.

166 PrfA controls the expression of major *Lm* virulence genes [31, 32]. We found a palindromic sequence  
167 TTAACAgATTCAA, bearing two mismatches with the consensus PrfA-box (TTAACAttTGTTAA), 661-bp  
168 upstream *cadC* start codon. PrfA-dependent *cadC* transcription was assessed on wild type (WT) and  $\Delta prfA$  strains  
169 grown in BHI or glycerol-supplemented minimal medium (MM), in presence of Cd. PrfA is fully active in MM [33].  
170 Levels of *cadC* transcripts were similar in both strains under both conditions (Fig.1D), demonstrating that PrfA  
171 does not control *cadC* expression.

172 Thus, *Lm* encodes a chromosomal putative Cd efflux system whose expression is Cd-dependent and PrfA-  
173 independent.

#### 174 **CadA is a functional cadmium efflux pump required for *Lm* resistance to cadmium**

175 Growth rates of single ( $\Delta cadA$ ,  $\Delta cadC$ ) and double ( $\Delta cadAC$ ) deletion mutants were comparable to that of WT  
176 strain (Fig.2A), indicating that none of the Cad proteins is essential for viability/growth in rich medium. Addition of  
177 Cd to mid-exponential cultures induced a slight decrease on WT and  $\Delta cadC$  growth, whereas it notably impaired  
178 the growth of  $\Delta cadA$  and  $\Delta cadAC$ , revealing the CadA role in *Lm* resistance to Cd. While growth inhibition zone  
179 registered when *Lm* lawns were grown on BHI plates overlaid with disks saturated with CdCl<sub>2</sub> was equivalent in  
180 WT and  $\Delta cadC$ ,  $\Delta cadA$  displayed increased Cd susceptibility (Fig.2B), confirming the role of CadA in Cd  
181 resistance and demonstrating that CadC is not required for Cd resistance. Similar areas of growth inhibition were  
182 observed with disks saturated either with CdCl<sub>2</sub> or CdSO<sub>4</sub> (Fig.2B), showing that Cd is the cause of toxicity. WT  
183 and  $\Delta cadA$  showed similar growth inhibition in response to all other metal salts tested (Fig.2B), indicating that



184 CadA mainly confers resistance to Cd. In agreement, as compared to WT,  $\Delta cadA$  displayed a 10-fold decrease in  
185 minimum inhibitory concentration (MIC) of Cd, while it remained unchanged for Zn, Co, Cu and Ni (Fig.2C). We  
186 measured intracellular levels of Cd, Zn and Pb in WT and  $\Delta cadA$ . Whereas Zn and Pb levels were equivalent in  
187 both strains,  $\Delta cadA$  accumulated nearly 6-fold more intracellular Cd (Fig.2D), demonstrating that CadA is required  
188 to maintain homeostatic intracellular Cd concentrations.  
189 These results confirm that *Lm*-CadA is a functional Cd efflux pump required to confer resistance to Cd-induced  
190 toxicity.

### 191 **CadC directly regulates *cadA*, *cadC* and *lspB* expression in response to cadmium**

192 We assessed the role of CadC and Cd in *cadA*, *cadC* and *lspB* transcription. In absence of CadC, *cadA* and *lspB*  
193 transcript levels were significantly increased, and *cadA*, *cadC* and *lspB* transcripts rose in response to Cd (Fig.3A),  
194 showing that CadC actively represses *cadA* and *lspB* transcription, whereas Cd activates *cadA*, *cadC* and *lspB*  
195 expression.

196 We identified conserved CadC-boxes (Cx) exclusively in the promoter regions of *cadA* (*cadA*-Cx), *cadC* (*cadC*-Cx)  
197 and *lspB* (*lspB*-Cx), similar to the well-characterized *Sa*-Cx (Fig.3B). *Lm* CadC was produced, purified (Fig.S2A)  
198 and used in EMSAs with DNA-fragments containing each Cx. CadC appeared capable to delay the migration of  
199 *cadA*-Cx, *cadC*-Cx and *lspB*-Cx (Fig.3B), but not of a negative control promoter DNA (*inlA*). Similarly, an unrelated  
200 protein (GFP) did not delay *cadC*-Cx migration. Thus, direct CadC binding to Cx appears to be sequence- and  
201 protein-specific. To confirm that *Lm*-CadC binds to Cx *in vivo*, CadC was immunoprecipitated from *Lm* extracts  
202 using an anti-CadC antibody, and co-precipitated DNA was analyzed by qPCR using primers specific for the  
203 different Cx (ChIP-qPCR). An enrichment was observed for all Cx tested (Fig.3B), and shown to be specific by  
204 normalization to a negative control DNA and to mock-IP, demonstrating the CadC binds specifically to *Lm*-Cx *in*  
205 *vivo*.

206 EMSAs were also performed with DNA fragments containing wild-type *cadC*-Cx sequence (Cx) or with point (Cx-  
207 M1-6) or transversed (Cx-T) mutations (Fig.3C). Whereas CadC altered the migration of native Cx, with the

exception of the M2 substitution (T→G), every other mutation abrogated the mobility shift. The CadC-Cx interaction appears thus highly specific and dependent on the conserved palindromic sequence. In the presence of increased concentrations of Cd, CadC was released from Cx (Fig.3D). In addition, the Cd concentration necessary to abrogate CadC binding to Cx was ten-fold lower than that required to prevent CadC binding to a DNA fragment containing two Cx (*cadA*-Cx-*lspB*-Cx). These results demonstrate that, in absence of Cd, CadC represses the expression of *cadAC* by directly binding conserved Cx present in *cadA* and *cadC* promoters. In presence of Cd, CadC cannot bind to or is detached from Cx, allowing CadA expression, thus inducing Cd resistance. The Cd concentration required to prevent CadC binding depends on the number of Cx. The expression of *lspB* is also subjected to Cd-dependent CadC-mediated regulation. However, *lspB* appears needless for Cd resistance (Fig.S2B).

#### **CadC is required for efficient *Lm* infection *in vivo***

We evaluated the role of CadAC during *Lm* infection *in vivo* by determining bacterial loads in liver and spleen of intravenously inoculated mice. 72h post-infection (p.i.), bacterial counts for the WT and  $\Delta cadA$  were similar in both organs (Fig.4A). However, they appeared significantly lower for  $\Delta cadC$  and  $\Delta cadAC$ . Complementation of the  $\Delta cadC$  mutant ( $\Delta cadC$ +*cadC*) restored bacterial loads to WT levels. Oral inoculation confirmed the impaired colonization of mouse organs by the  $\Delta cadC$  and  $\Delta cadAC$  as compared to the WT and  $\Delta cadA$  strains (Fig.4B). CadC thus plays a role in *Lm in vivo* infection, independent of *cadA* expression.

#### **In absence of CadC repression, *lspB* expression is deleterious for *Lm* infection**

CadC being overexpressed in mouse organs [12], we postulated that CadC-dependent *lspB* repression would be necessary for efficient *Lm* infection. We constructed  $\Delta lspB$  and  $\Delta cadC\Delta lspB$  mutants and a *lspB*-overexpressing strain (WT+*lspB*). Analysis of growth rates and *lspB* transcription indicated that neither the absence nor the overexpression of *lspB* have significant impact on *Lm* viability/replication in rich medium (Fig.S2DE). TEM micrographs revealed no difference regarding overall and cell wall morphology of *lspB*-overexpressing strains (Fig.S2F). 72h post mouse intravenous (Fig.4C) or oral (Fig.4D) inoculation, bacterial counts for the WT and  $\Delta lspB$

232 were not significantly different, indicating that *LspB* is not required for *Lm* infection. Interestingly, whereas  $\Delta cadC$   
233 bacteria were attenuated (Fig.4AD),  $\Delta cadC\Delta lspB$  behaved like the WT (Fig.4CD), suggesting that the  $\Delta cadC$   
234 phenotype is associated to *lspB* expression levels. In agreement, the *lspB*-overexpressing strain appeared  
235 significantly attenuated both after intravenous (Fig.4C) or oral (Fig.4D) inoculation.

236 Increased *lspB* expression, either through the absence of *CadC* repression or through overexpression, appears  
237 thus detrimental for the *Lm* infectious capacity.

### 238 ***LspB* controls *LpeA* extracellular release**

239 *LspB* has a high identity degree with known signal-peptidase-type-II (SPase-II) from other *Listeria* strains and  
240 bacterial species (Fig.5A), in particular with the *S. thermophilus* (St) SPase-II (75% identity). *LspB* harbors the five  
241 highly conserved SPase-II domains and the six residues critical for SPase-II activity [34]. Predicted *LspB* topology  
242 shows the presence of four transmembrane domains, suggesting a membrane localization (Fig.S1D). SPases-II  
243 were shown to be involved in lipoprotein membrane insertion and release to the extracellular medium [35]. We  
244 thus hypothesized that differential *lspB* expression could result in changes in the repertoire of *Lm* surface-exposed  
245 and/or released lipoproteins. Whereas no difference was observed in membrane lipoprotein extracts, a band was  
246 detected between 25-37 kDa with increased intensity in culture supernatants from *lspB*-overexpressing strains  
247 ( $\Delta cadC$ , WT+*lspB*) (Fig.5BC). The protein present in this band was identified by mass spectrometry as the *Lm*  
248 lipoprotein *LpeA* (Lipoprotein promoting entry A) [36] (Tab.S3). *LspA* was the first SPase-II identified in *Lm* [44].  
249 We analyzed *lspA* expression levels and showed that they were similar in the different strains (Fig.S3A), indicating  
250 that increased *LpeA* levels in culture supernatants from *lspB*-overexpressing strains are unrelated to a differential  
251 *lspA* expression.

252 Thus, *lspB* encodes a secondary *Lm* SPase-II which promotes the release of the *LpeA* lipoprotein to the  
253 extracellular medium.

### 254 ***LspB* derepression induces expression of inflammatory cytokines limiting intramacrophagic survival**

255 LpeA was shown to be required for entry into intestinal and hepatic cells [36]. In addition, a LpeA-deficient mutant  
256 survives longer in macrophages and is slightly more virulent in mice than WT bacteria [36]. We thus hypothesized  
257 that in presence of high LspB levels, more LpeA would be found in the extracellular medium, which would  
258 decrease *Lm* survival in macrophages. We analyzed the capacity of *Lm* strains to survive in mouse bone marrow-  
259 derived macrophages (BMDM). Whereas no significant difference was observed at 30 min p.i. (Fig.6A),  
260 intramacrophagic survival of  $\Delta cadC$ ,  $\Delta cadAC$ , and WT+*lspB* were significantly decreased 5 h p.i., as compared to  
261 WT bacteria (Fig.6B).  $\Delta cadA$ ,  $\Delta cadC+cadC$ ,  $\Delta lspB$  and  $\Delta cadC\Delta lspB$  behaved similarly to WT. These results  
262 indicate that *Lm* phagocytosis is not dependent on CadA, CadC or LspB; high *lspB* expression is detrimental for  
263 *Lm* intramacrophagic survival; CadC-mediated repression avoids LspB disruptive effects on *Lm* infection; and the  
264  $\Delta cadC$  phenotype *in vivo* is not related to *cadA* de-repression.

265 Secreted *Lm* lipoproteins were shown to induce inflammatory cytokines (TNF- $\alpha$  and IL-6) in a TLR2-dependent  
266 manner during infection [37]. Given that *lspB* overexpression results in higher LpeA levels in culture supernatants,  
267 we tested if this increased lipoprotein release could promote inflammatory cytokine expression. RAW  
268 macrophages were infected and 5 h p.i TNF- $\alpha$  and IL-6 expression and secretion levels were assessed. In  $\Delta lspB$ -  
269 and  $\Delta lpeA$ -infected RAW, TNF- $\alpha$  and IL-6 levels were significantly reduced. Inversely, infection by *lspB*-  
270 overexpressing bacteria resulted in increased cytokine expression/secretion (Fig.6CD). As observed in BMDM, the  
271 WT+*lspB* strain showed a significantly reduced capacity to survive in RAW macrophages (Fig.S3B).

272 *Lm* thus uses CadC to repress *lspB* expression during infection, avoiding excessive LpeA exposure to the host  
273 immune system, reducing inflammatory response and promoting intramacrophagic survival and virulence.

274

## 275 **DISCUSSION**

276 CadA is an efflux pump required for Cd resistance, but in contrast to its homologues in *Sa* and *St* [38, 39], it is not  
277 essential for zinc and lead efflux and does not significantly contribute to resistance against these or other metals.  
278 Whereas *Lm*-CadA was proposed to alternatively transport zinc [40], resistance to zinc was previously shown to

279 be independent on *Lm*-CadAC [11]. Albeit we cannot exclude that *Lm*-CadA might participate in detoxification of  
280 high levels of zinc, it mainly acts as a Cd efflux pump.

281 *Lm*-CadC appears as a *trans*-acting, sequence-specific, DNA-binding and Cd-dependent regulator of *cadA*, *cadC*  
282 and *lspB* expression. We show for the first time that the conservation of almost every nucleotide within the Cx  
283 palindrome is crucial for CadC binding. As previously suggested [39], we also show that Cd concentration  
284 necessary to release CadC from DNA is proportional to the number of Cx. Whereas *cadAC* are generally part of  
285 an operon under the control of a unique promoter containing two Cx, in *Lm* these two genes are non-contiguous  
286 and controlled by two different Cx-containing promoters. They are separated by *lspB* with the opposite orientation  
287 and two Cx between *cadA* and *lspB*. This suggests that *Lm* evolved an additional regulation level allowing a  
288 differential regulation of *cadA* and *cadC*. *Lm* appears also as the first bacterium shown to use a Cd efflux pump  
289 repressor to control genes unrelated with Cd resistance. This atypical organization of the *cadAC* locus, i.e. split by  
290 a SPase-encoding gene, is only found with a remarkable conservation in a cis-mobilisable element of *St* [41]. The  
291 chromosomal *Lm*-*cadAC* locus is predicted as part of a *Lm* integrative and conjugative element [41], and its GC%  
292 is markedly lower than that of the surrounding regions, suggesting that *Lm* could have acquired this locus by  
293 horizontal gene transfer.

294 We demonstrate that during infection *Lm* represses *lspB* via CadC to ensure maximal infection efficiency. LspB, as  
295 other Gram-positive SPases-II [42], is dispensable for bacterial growth *in vitro* and for virulence *in vivo*. SPases-II  
296 specifically process the N-terminal signal peptide of prolipoproteins translocated through the Sec system and  
297 lipidated by a diacylglyceryltransferase (Lgt). Lipoproteins are ultimately chained to the membrane *via* a lipid  
298 moiety covalently bound to an N-terminal conserved cysteine [43]. In addition to the presence in its sequence of all  
299 the conserved domains/residues critical for SPase-II activity [34] and its predicted membrane localization, our  
300 results point LspB as a secondary *Lm* SPase-II involved in the processing of LpeA. However, we cannot exclude  
301 that LspB could act upon other lipoproteins. LspA, the first SPase-II identified in *Lm*, is involved in lipoprotein  
302 processing, including LpeA, and in macrophage phagosome escape [44]. LspA is also involved in lipoprotein  
303 release to the extracellular medium, a process also dependent on Lgt. The retention/release of lipoproteins

304 appears thus as a complex process in *Lm*, co-controlled by Lgt and SPases.

305 LpeA can be secreted, in particular in absence of Lgt [35, 45]. In a *lgt* mutant, soluble lipoproteins induce the

306 secretion of inflammatory cytokines in a TLR2-dependent manner during infection [37]. *lspB* de-repression/over-

307 expression leads to increased LpeA release and inflammatory cytokines secretion, and correlates with decreased

308 intramacrophage survival and virulence in mice. Interestingly, an *lpeA* mutant survives better inside macrophages

309 and induced early mouse mortality [36]. Group-B *Streptococcus* secreted lipoproteins also activate host

310 inflammatory response through TLR2-signalling [42]. In this model, absence of *lgt* and/or *lsp* leads to decreased

311 TLR2-mediated recognition, reduced inflammatory response, and increased lethality [42]. Secreted mycoplasma

312 lipoproteins also have the ability to modulate the host immune system in a TLR2-dependent manner [46]. Bacteria

313 use thus differently lipoprotein processing enzymes (Lgt, Lsp) to control lipoprotein exposure to host immune

314 recognition mechanisms. While LpeA is required for host cell invasion [36], it also activates host-protective

315 inflammatory responses. To reach a midpoint, *Lm* developed an original strategy to spatially and temporally

316 regulate LpeA exposure at the bacterial surface and to the host immune system. Interestingly, *Lm* downregulates

317 *lgt*, *lspA* and *lspB* and upregulates *cadC* during mouse infection (Tab.S2) [12], suggesting that the localization of

318 *Lm* lipoproteins is tightly regulated during infection to promote virulence.

319 We propose that *Lm* acquired a mobile element containing the *cadA-lspB-cadC* locus to control lipoprotein

320 localization via CadC-dependent *lspB* regulation. During infection, this process minimizes lipoprotein exposure to

321 the host immune system, diminishing inflammatory cytokine expression and promoting intramacrophagic survival

322 and infection. This constitutes the first example of a heavy metal efflux pump regulator repurposed by a bacterial

323 pathogen to fine-tune lipoprotein localization and host immune responses during infection. Being non-essential for

324 bacterial growth, these transcriptional repressors could represent new targets for innovative antibacterial

325 strategies.

326

327 **Word count: 3 490**

328

329

330 **ACKNOWLEDGEMENTS**

331 We thank J.H. Morais-Cabral and R. Adaixo (Group of Structural Biochemistry, IBMC) for their help in 3D structure  
332 comparison. We thank R. Appelberg for PhD co-supervision of R.P., A.C., O.R., F.C., MT.A. and J.C.P. We thank  
333 S. Lamas (Animal Facility), F. Silva (B2Tech), H. Osorio (PCF), P. Magalhães (CCGEN) and R. Fernandes  
334 (HEMS) from IBMC facilities for technical assistance.

335

336

## REFERENCES

1. Saier MH, Jr., Paulsen IT, Sliwinski MK, Pao SS, Skurray RA, Nikaido H. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. *Faseb J* **1998**; 12:265-74.
2. Nies DH. Efflux-mediated heavy metal resistance in prokaryotes. *FEMS Microbiol Rev* **2003**; 27:313-39.
3. Endo G, Silver S. CadC, the transcriptional regulatory protein of the cadmium resistance system of *Staphylococcus aureus* plasmid pI258. *J Bacteriol* **1995**; 177:4437-41.
4. Osman D, Cavet JS. Bacterial metal-sensing proteins exemplified by ArsR-SmtB family repressors. *Nat Prod Rep* **2010**; 27:668-80.
5. Busenlehner LS, Weng TC, Penner-Hahn JE, Giedroc DP. Elucidation of primary ( $\alpha(3)N$ ) and vestigial ( $\alpha(5)$ ) heavy metal-binding sites in *Staphylococcus aureus* pI258 CadC: evolutionary implications for metal ion selectivity of ArsR/SmtB metal sensor proteins. *J Mol Biol* **2002**; 319:685-701.
6. Nucifora G, Chu L, Misra TK, Silver S. Cadmium resistance from *Staphylococcus aureus* plasmid pI258 *cadA* gene results from a cadmium-efflux ATPase. *Proc Natl Acad Sci U S A* **1989**; 86:3544-8.
7. Cossart P. Illuminating the landscape of host-pathogen interactions with the bacterium *Listeria monocytogenes*. *Proc Natl Acad Sci U S A* **2011**; 108:19484-91.
8. European Food Safety Authority ECfDPaC. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2013. European Food Safety Authority, European Centre for Disease Prevention and Control *EFSA Journal* **2015**; 13:3991.
9. Swaminathan B, Gerner-Smidt P. The epidemiology of human listeriosis. *Microbes Infect* **2007**; 9:1236-43.
10. Lebrun M, Audurier A, Cossart P. Plasmid-borne cadmium resistance genes in *Listeria monocytogenes* are present on Tn5422, a novel transposon closely related to Tn917. *J Bacteriol* **1994**; 176:3049-61.
11. Lebrun M, Audurier A, Cossart P. Plasmid-borne cadmium resistance genes in *Listeria monocytogenes* are similar to *cadA* and *cadC* of *Staphylococcus aureus* and are induced by cadmium. *J Bacteriol* **1994**; 176:3040-8.
12. Camejo A, Buchrieser C, Couve E, et al. In vivo transcriptional profiling of *Listeria monocytogenes* and mutagenesis identify new virulence factors involved in infection. *PLoS Pathog* **2009**; 5:e1000449.



- 362 13. Glaser P, Frangeul L, Buchrieser C, et al. Comparative genomics of *Listeria* species. *Science* **2001**; 294:849-  
363 52.
- 364 14. Lauer P, Chow MY, Loessner MJ, Portnoy DA, Calendar R. Construction, characterization, and use of two  
365 *Listeria monocytogenes* site-specific phage integration vectors. *J Bacteriol* **2002**; 184:4177-86.
- 366 15. Reis O, Sousa S, Camejo A, et al. LapB, a novel *Listeria monocytogenes* LPXTG surface adhesin, required for  
367 entry into eukaryotic cells and virulence. *J Infect Dis* **2010**; 202:551-62.
- 368 16. Sullivan MA, Yasbin RE, Young FE. New shuttle vectors for *Bacillus subtilis* and *Escherichia coli* which allow  
369 rapid detection of inserted fragments. *Gene* **1984**; 29:21-6.
- 370 17. Archambaud C, Gouin E, Pizarro-Cerda J, Cossart P, Dussurget O. Translation elongation factor EF-Tu is a  
371 target for Stp, a serine-threonine phosphatase involved in virulence of *Listeria monocytogenes*. *Mol Microbiol*  
372 **2005**; 56:383-96.
- 373 18. Leimeister-Wachter M, Domann E, Chakraborty T. The expression of virulence genes in *Listeria*  
374 *monocytogenes* is thermoregulated. *J Bacteriol* **1992**; 174:947-52.
- 375 19. Kurokawa K, Lee H, Roh KB, et al. The Triacylated ATP Binding Cluster Transporter Substrate-binding  
376 Lipoprotein of *Staphylococcus aureus* Functions as a Native Ligand for Toll-like Receptor 2. *J Biol Chem* **2009**;  
377 284:8406-11.
- 378 20. Pinheiro J, Reis O, Vieira A, et al. *Listeria monocytogenes* encodes a functional ESX-1 secretion system  
379 whose expression is detrimental to in vivo infection. *Virulence* **2016**:0.
- 380 21. Almeida MT, Mesquita FS, Cruz R, et al. Src-dependent tyrosine phosphorylation of non-muscle myosin heavy  
381 chain-IIA restricts *Listeria monocytogenes* cellular infection. *J Biol Chem* **2015**; 290:8383-95.
- 382 22. Lobel L, Sigal N, Borovok I, Belitsky BR, Sonenshein AL, Herskovits AA. The metabolic regulator CodY links  
383 *Listeria monocytogenes* metabolism to virulence by directly activating the virulence regulatory gene *prfA*. *Mol*  
384 *Microbiol* **2015**; 95:624-44.
- 385 23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the  
386  $2^{-\Delta\Delta C(T)}$  Method. *Methods* **2001**; 25:402-8.

387 24. Cabanes D, Lecuit M, Cossart P. Animal models of *Listeria* infection. *Curr Protoc Microbiol* **2008**; Chapter  
388 9:Unit9B 1.

389 25. Sun Y, Wong MD, Rosen BP. Role of cysteinyl residues in sensing Pb(II), Cd(II), and Zn(II) by the plasmid  
390 pI258 CadC repressor. *J Biol Chem* **2001**; 276:14955-60.

391 26. Kandegedara A, Thiyagarajan S, Kondapalli KC, Stemmler TL, Rosen BP. Role of bound Zn(II) in the CadC  
392 Cd(II)/Pb(II)/Zn(II)-responsive repressor. *J Biol Chem* **2009**; 284:14958-65.

393 27. Kuhlbrandt W. Biology, structure and mechanism of P-type ATPases. *Nat Rev Mol Cell Biol* **2004**; 5:282-95.

394 28. Kuenne C, Voget S, Pischmarov J, et al. Comparative analysis of plasmids in the genus *Listeria*. *PLoS One*  
395 **2010**; 5.

396 29. Bierne H, Cossart P. *Listeria monocytogenes* surface proteins: from genome predictions to function. *Microbiol*  
397 *Mol Biol Rev* **2007**; 71:377-97.

398 30. Desvaux M, Hebraud M. The protein secretion systems in *Listeria*: inside out bacterial virulence. *FEMS*  
399 *Microbiol Rev* **2006**; 30:774-805.

400 31. Milohanic E, Glaser P, Coppee JY, et al. Transcriptome analysis of *Listeria monocytogenes* identifies three  
401 groups of genes differently regulated by PrfA. *Mol Microbiol* **2003**; 47:1613-25.

402 32. Scotti M, Monzo HJ, Lacharme-Lora L, Lewis DA, Vazquez-Boland JA. The PrfA virulence regulon. *Microbes*  
403 *Infect* **2007**; 9:1196-207.

404 33. Stoll R, Mertins S, Joseph B, Muller-Altroch S, Goebel W. Modulation of PrfA activity in *Listeria*  
405 *monocytogenes* upon growth in different culture media. *Microbiology* **2008**; 154:3856-76.

406 34. Tjalsma H, Zanen G, Venema G, Bron S, van Dijk JM. The potential active site of the lipoprotein-specific (type  
407 II) signal peptidase of *Bacillus subtilis*. *J Biol Chem* **1999**; 274:28191-7.

408 35. Baumgartner M, Karst U, Gerstel B, Loessner M, Wehland J, Jansch L. Inactivation of Lgt allows systematic  
409 characterization of lipoproteins from *Listeria monocytogenes*. *J Bacteriol* **2007**; 189:313-24.

410 36. Reglier-Poupet H, Pellegrini E, Charbit A, Berche P. Identification of LpeA, a PsaA-like membrane protein that  
411 promotes cell entry by *Listeria monocytogenes*. *Infect Immun* **2003**; 71:474-82.

- 412 37. Machata S, Tchatalbachev S, Mohamed W, Jansch L, Hain T, Chakraborty T. Lipoproteins of *Listeria*  
413 *monocytogenes* are critical for virulence and TLR2-mediated immune activation. *J Immunol* **2008**; 181:2028-35.
- 414 38. Yoon KP, Silver S. A second gene in the *Staphylococcus aureus* cadA cadmium resistance determinant of  
415 plasmid pI258. *J Bacteriol* **1991**; 173:7636-42.
- 416 39. Schirawski J, Hagens W, Fitzgerald GF, Van Sinderen D. Molecular characterization of cadmium resistance in  
417 *Streptococcus thermophilus* strain 4134: an example of lateral gene transfer. *Appl Environ Microbiol* **2002**;  
418 68:5508-16.
- 419 40. Banci L, Bertini I, Ciofi-Baffoni S, et al. Structural basis for metal binding specificity: the N-terminal cadmium  
420 binding domain of the P1-type ATPase CadA. *J Mol Biol* **2006**; 356:638-50.
- 421 41. Pavlovic G, Burrus V, Gintz B, Decaris B, Guedon G. Evolution of genomic islands by deletion and tandem  
422 accretion by site-specific recombination: ICEst1-related elements from *Streptococcus thermophilus*. *Microbiology*  
423 **2004**; 150:759-74.
- 424 42. Henneke P, Dramsi S, Mancuso G, et al. Lipoproteins are critical TLR2 activating toxins in group B  
425 streptococcal sepsis. *J Immunol* **2008**; 180:6149-58.
- 426 43. Sankaran K, Wu HC. Lipid modification of bacterial prolipoprotein. Transfer of diacylglycerol moiety from  
427 phosphatidylglycerol. *J Biol Chem* **1994**; 269:19701-6.
- 428 44. Reglier-Poupet H, Frehel C, Dubail I, et al. Maturation of lipoproteins by type II signal peptidase is required for  
429 phagosomal escape of *Listeria monocytogenes*. *J Biol Chem* **2003**; 278:49469-77.
- 430 45. Trost M, Wehmhoner D, Karst U, Dieterich G, Wehland J, Jansch L. Comparative proteome analysis of  
431 secretory proteins from pathogenic and nonpathogenic *Listeria* species. *Proteomics* **2005**; 5:1544-57.
- 432 46. Seya T, Matsumoto M. A lipoprotein family from *Mycoplasma fermentans* confers host immune activation  
433 through Toll-like receptor 2. *Int J Biochem Cell Biol* **2002**; 34:901-6.
- 434 47. Dramsi S, Kocks C, Forestier C, Cossart P. Internalin-mediated invasion of epithelial cells by *Listeria*  
435 *monocytogenes* is regulated by the bacterial growth state, temperature and the pleiotropic activator prfA. *Mol*  
436 *Microbiol* **1993**; 9:931-41.

437 48. Claros MG, von Heijne G. TopPred II: an improved software for membrane protein structure predictions.  
438 Comput Appl Biosci **1994**; 10:685-6.

439

440

## 441 **FIGURE LEGENDS**

442

### 443 **Figure 1. Identification of a cadmium resistance system in the genome of *Lm***

444 (A) Alignment of the CadC and CadA protein sequences of *Lm* and *Sa* pl258. Metal-binding sites 1 (red boxes)  
445 and 2 (blue boxes) are indicated. Green box indicates CXXC metal-binding site. Yellow box shows CPC motif and  
446 orange box indicates DKTGTLT sequence. (B) *Lm* genomic organization and GC content of the region  
447 encompassing *cadAC*. Variations in the DNA GC% relative to the average GC% of the whole genome are  
448 indicated by bars. Numbers correspond to the GC% for each gene. (C) Transcriptional analysis of the *cadA-lspB-*  
449 *cadC* region by RT-PCR. Predicted fragments (*cadA*, *cadA-lspB*, *lspB*, *lspB-cadC* and *cadC*) amplified with the  
450 different primer sets are indicated on the schematic representation of the *cadA-lspB-cadC* locus. RT-PCRs were  
451 performed on RNAs from logarithmic cultures of *Lm* growing in BHI broth at 37°C, in the absence (-) or presence  
452 (+) of cadmium (Cd). Control PCRs were performed on genomic DNA. (D) Analysis of PrfA regulation of *cadC*  
453 transcription. Quantitative real-time PCR was performed on RNAs extracted from logarithmic cultures of WT and  
454  $\Delta prfA$  strains grown in BHI at 37°C. *inlA* and *lmo2845* were used as PrfA-dependent and PrfA-independent control  
455 genes, respectively [47] [15]. Gene expression levels in the  $\Delta prfA$  mutant are presented normalized to those in the  
456 WT (set at 1). Values are mean  $\pm$  SD from 3 independent experiments. Statistical significance is indicated as  
457 compared to WT: \* $P < 0.05$

458

### 459 **Figure 2. CadA behaves as a cadmium efflux pump required for *Lm* resistance to cadmium**

460 (A) Growth curves of the WT,  $\Delta cadA$ ,  $\Delta cadC$  and  $\Delta cadAC$  strains in BHI at 37°C and challenged at t=210 min  
461 with 384  $\mu$ M CdCl<sub>2</sub>. Representative results from three independent experiments. (B) Growth inhibition of WT,

462  $\Delta cadA$  and  $\Delta cadC$  strains in agar medium overlaid with disks saturated with 100 mM  $CdCl_2$  or  $CdSO_4$ , or with 100  
 463 mM of zinc (Zn), lead (Pb), manganese (Mn), cobalt (Co), copper (Cu), calcium (Ca), magnesium (Mg) or nickel  
 464 (Ni) salts. Values are mean  $\pm$  SD from 5 independent experiments. (C) MICs of cadmium, zinc, cobalt, copper and  
 465 nickel for the WT and  $\Delta cadA$  strains. (D) Intracellular levels of cadmium, zinc and lead measured by ICP-MS in the  
 466 WT and  $\Delta cadA$  strains. Values are mean  $\pm$  SD from 3 independent experiments. \* $P$ <0.05 and \*\*\* $P$ <0.001.

### 468 **Figure 3. CadC directly regulates *cadA*, *cadC* and *lspB* expression in response to cadmium**

469 (A) *cadA*, *cadC* and *lspB* transcription is dependent on CadC and Cd concentration. qRT-PCRs on RNAs  
 470 extracted from logarithmic cultures of WT and  $\Delta cadC$  grown in BHI at 37°C and WT grown in BHI supplemented  
 471 with Cd (WT+Cd). *Imo2845* was used as a CadC- and Cd-independent control gene. Gene expression levels are  
 472 shown normalized to those in the WT grown in BHI in absence of Cd (set at 1). Values are mean  $\pm$  SD from 3  
 473 independent experiments. Statistical significance is indicated as compared to WT: \* $P$ <0.05 and \*\* $P$ <0.01. (B)  
 474 CadC binds directly *cadA*, *cadC* and *lspB* CadC box. (Upper panel) Alignment of CadC boxes upstream of *Sa*  
 475 *p1258 cadC* (*SacadC*), *Lm cadA* (*LmcadA*), *Lm cadC* (*LmcadC*) and *Lm lspB* (*LmlspB*). Palindromes are indicated  
 476 by arrows. (Bottom left panel) Increasing amounts of purified CadC were used in electrophoretic mobility shift  
 477 assays (EMSAs) with DNA fragments containing the *cadA*, *cadC* or *lspB* CadC box (Cx) generated by PCR using  
 478 primers listed in Table S1. An unrelated promoter region (*inlA*) and an unrelated protein (GFP) were used as  
 479 negative controls. (Bottom right panel) ChIP-qPCR was conducted to quantify the capacity of CadC to bind Cx *in*  
 480 *vivo*. Fold enrichment is shown normalized to an unrelated promoter region (*inlA*) and as compared to mock-IP.  
 481 Values are mean  $\pm$  SD from 5 independent experiments. \* $P$ <0.05. (C) Specificity of the CadC-Cx interaction using  
 482 Cx-containing DNA fragments in which the palindromic sequence was either present in its unaltered form (Cx), or  
 483 containing point (Cx-M1-5), or transversed (Cx-T) mutations (indicated in red). (D) In the presence of Cd, CadC  
 484 fails to bind *cadA*, *cadC* and *lspB* Cx. Increasing amounts of  $CdCl_2$  were used in EMSAs with purified CadC and  
 485 *cadA* Cx, *cadA* Cx-*lspB* Cx and *cadC* Cx DNA fragments. (B-D) Experiments were performed at least twice, and  
 486 representative results are shown.

488 **Figure 4. In absence of CadC repression, *lspB* expression is deleterious for *Lm* infectious capacity**

489 (A) Bacterial counts of the WT,  $\Delta cadA$ ,  $\Delta cadC$ ,  $\Delta cadAC$  and  $\Delta cadC+cadC$  strains in the liver and spleen of  
 490 C57BL/6 mice 72h after intravenous inoculation of  $10^5$  bacteria per animal. (B) Bacterial counts of the WT,  $\Delta cadA$ ,  
 491  $\Delta cadC$  and  $\Delta cadAC$  strains in the liver and spleen of C57BL/6 mice 72h after oral inoculation of  $10^9$  bacteria per  
 492 animal. (C) Bacterial counts of the WT,  $\Delta lspB$ ,  $\Delta cadC\Delta lspB$  and WT+*lspB* strains in the liver and spleen of  
 493 C57BL/6 mice 72h after intravenous inoculation of  $10^5$  bacteria per animal. (D) Bacterial counts of the WT,  $\Delta lspB$ ,  
 494  $\Delta cadC\Delta lspB$  and WT+*lspB* strains in the liver and spleen of BALB/c mice 72h after oral inoculation of  $10^9$  bacteria  
 495 per animal. Data are presented as scatter plots, with each animal indicated by empty circle and the mean  
 496 indicated by a horizontal line. (n=5). \* $P<0.05$ , \*\* $P<0.01$  and \*\*\* $P<0.001$ .

497

498 **Figure 5. *LspB* controls *LpeA* release in the extracellular medium**

499 (A) Alignment of the protein sequence of SPases II from *Lm* (*Lm LspA* and *Lm LspB*), *Listeria innocua* (*Lin Lsp*),  
 500 *Bacillus subtilis* (*Bs Lsp*), *Sa* (*Sa Lsp*) and *St* (*St Lsp*). Residues present in at least 3 SPases II are in blue while  
 501 residues conserved in all SPases II are shown in red. Conserved domains (I-V) as defined by Tjalsma *et al.* [34],  
 502 are highlighted in green boxes. Residues important for activity/stability are indicated by green arrows. (B)  
 503 Lipoprotein membrane extracts and culture supernatants from the WT,  $\Delta cadC$ ,  $\Delta lspB$ ,  $\Delta cadC\Delta lspB$  and WT+*lspB*  
 504 strains separated by SDS-PAGE and stained with Coomassie Blue. Arrows indicate a band between 25 and 37  
 505 kDa with increased intensity in the culture supernatants from  $\Delta cadC$  and WT+*lspB* strains. (C) Quantifications of  
 506 *LpeA* in culture supernatants (ImageJ). Values are mean  $\pm$  SD from 3 independent experiments and are  
 507 presented normalized to loading control and as percentage relative to the mean of WT band intensity (set at 100).  
 508 \* $P<0.05$  and \*\* $P<0.01$ .

509

510 **Figure 6. In absence of CadC repression, *lspB* expression decreases *Lm* survival in macrophages and**  
 511 **induces inflammatory cytokine expression**

512 (A-B) Intracellular numbers of the WT,  $\Delta cadA$ ,  $\Delta cadC$ ,  $\Delta cadC+cadC$ ,  $\Delta cadAC$ ,  $\Delta lspB$ , WT+*lspB* and  $\Delta cadC\Delta lspB$   
 513 strains in mouse bone marrow-derived macrophages (BMDM) at (A) 30 min and (B) 5 h post-infection (p.i.).  
 514 Values are mean  $\pm$  SD from 3 independent experiments and are presented as percentage relative to the mean of  
 515 WT bacterial counts (set at 100). Statistical significance is indicated as compared to WT: \* $P<0.05$ , \*\* $P<0.01$  and  
 516 \*\*\* $P<0.001$ , or between indicated strains: ### $P<0.001$ . (C-D) Quantification of TNF- $\alpha$  and IL-6 expression levels by  
 517 qRT-PCR (C) and secretion levels by ELISA (D) at 5 h p.i. of RAW macrophages with either WT,  $\Delta lspB$ , WT+*lspB*  
 518 or  $\Delta peA$  strains. Values are mean  $\pm$  SD from 3 independent experiments. Statistical significance is indicated as  
 519 compared to WT: \* $P<0.05$ , \*\* $P<0.01$  and \*\*\* $P<0.001$ .

520

521 **Figure S1.** (A) Amino acid identity between CadC and CadA proteins from *Lm* and other bacteria. (B) Comparison  
 522 of the 3D structure of Sa pl258 CadC dimer (blue and green) and the predicted 3D structure of *Lm* CadC dimer  
 523 (red). The *Lm*-CadC structure was predicted using I-TASSER and matched to the solved structure of Sa pl258  
 524 CadC with PyMOL software. (C) Membrane topology model of *Lm* CadA as predicted by TopPred II software [48].  
 525 (D) Model for the membrane topology of LspB. The orientation of putative transmembrane regions was predicted  
 526 with the TopPred II software [48]. Conserved domains I-V are indicated.

527

528 **Figure S2.** (A) Purification of recombinant CadC protein. SDS-PAGE analysis of Ni-NTA agarose column  
 529 chromatography of CadC-His<sub>6</sub> protein after Coomassie blue staining. (B). Growth curves of the WT,  $\Delta cadA$ ,  $\Delta lspB$   
 530 and  $\Delta cadC\Delta lspB$  strains in BHI at 37°C and challenged at t=210 min with 384  $\mu$ M CdCl<sub>2</sub>. (C) Growth curves of the  
 531 WT,  $\Delta cadA$ ,  $\Delta cadC$ , and  $\Delta cadC+cadC$  strains in BHI at 37°C. (D) Growth curves of the WT,  $\Delta lspB$ ,  $\Delta cadC\Delta lspB$   
 532 and WT+*lspB* strains in BHI at 37°C. (E) RT-PCR analysis of the *lspB* expression in WT and WT+*lspB* strains. (F)  
 533 Transmission electron microscopy analysis of the WT,  $\Delta cadC$  and WT+*lspB* bacteria. Scale bar: 0.2  $\mu$ m.

534

535 **Figure S3.** (A) Analysis of *lspA* expression. Quantitative real-time PCR was performed on RNAs extracted from  
 536 logarithmic cultures of WT,  $\Delta cadC$ ,  $\Delta lspB$ ,  $\Delta cadC\Delta lspB$  and WT+*lspB* strains grown in BHI at 37°C. Gene

537 expression levels are presented normalized to those in the WT (set at 1). Values are mean  $\pm$  SD from 3  
538 independent experiments. (B) Intracellular multiplication of the WT and WT+*spB* strains in RAW macrophages at  
539 5 h p.i. Values are mean  $\pm$  SD from 3 independent experiments and are presented as percentage relative to the  
540 mean of WT bacterial counts (set at 100). Statistical significance is indicated as compared to WT: \*\* $P < 0.01$ .



**Table S1 - Primers**

Primer name	Sequence (5' to 3')
Primers used for mutagenesis	
<i>Imo1100MA</i>	ATAGTCGACAGTAGCGACTACTTCACACC
<i>Imo1100MB</i>	CGACGCGTCATAAAATTCCTCCTTTTTTC
<i>Imo1100MC</i>	CGACGCGTCTAATGAACTTACAAGG
<i>Imo1100MD</i>	CGCAGATCTAACTTTGTTTCTAACATTTCG
<i>Imo1101MA</i>	ATAGTCGACCAACATCATCACGACGTA
<i>Imo1101MB</i>	CGAATTCCATATCAACTCACTTGGAG
<i>Imo1101MC</i>	CGAATTCTAGCCTTTTTTCAAGTAGAAG
<i>Imo1101MD</i>	CAACCATGGGTGACGGAAGTGTGGACGCA
<i>Imo1102MA</i>	CGAGTCGACTTCCCACTATCAAAGTGG
<i>Imo1102MB</i>	CGAATTCCACGTTCCCTAAACACTCC
<i>Imo1102MC</i>	CGAATTCTAAAAAATCTTCAAACAC
<i>Imo1102MD</i>	CGCAGATCTAATTCGTACAAGACATACC
<i>lpeAMA</i>	AGAGCTCGGGTGTTCCAGTCAAATAGC
<i>lpeAMD</i>	ACAGTCGACGCCTTTTTTGCAGTGGAGTC
Primers used for complementation	
<i>Imo1102CG</i>	GCCACTAGTAACCCTGTTTACACACAAGC
<i>Imo1102CH</i>	ACCGTCGACTAGTCCGTGACTCTTTAGAC
Primers used for overexpression	
<i>Imo1101OA</i>	GACGGATCCGAGTTGATATGAAAAATAAGAC
<i>Imo1101OB</i>	CAGCTGCAGGCTACATTTTTTTGTAATAAC
Primers used for cloning in pET28b	
<i>Imo1102P1</i>	TACCATGGTGAATGACATTTGTGAAATAAC
<i>Imo1102P2</i>	ACTCGAGAAGTACAATATCTTTGATTAATG
Primers used for qRT-PCR	
<i>16SqF</i>	CTCGTGTGCTGAGATGTTGG
<i>16SqR</i>	CGTGTGTAGCCCAGGTCATA
<i>inIAqF</i>	ACAACTGGAGGGAACGCGCC
<i>inIAqR</i>	CCAGGTATATTTGCGGAAGG
<i>Imo1100qF</i>	TGAACGAGCACCAGCACAAGCG
<i>Imo1100qR</i>	CCCATGTGTCCCAATCACCACC
<i>Imo1101qF</i>	TCAAGATAACATACGCTCAA
<i>Imo1101qR</i>	CCATTAACGCTACTCCAA
<i>Imo1102qF</i>	AAGCCCTATCTGAAGAACTAGG
<i>Imo1102aR</i>	CGCTACTGTTGATTTACAATG
<i>Imo2845qF</i>	GGTGTAGGAAGTCCATCGGACC
<i>Imo2845qR</i>	ACTGCGCGCCAACCATTTGTAGC
<i>hprt1qF</i>	TGATTAGCGATGATGAACCA
<i>hprt1qR</i>	GTCTTTCAGTCCTGTCCATAA
<i>TNF<math>\alpha</math>qF</i>	CCAAAGGGATGAGAAGTTC
<i>TNF<math>\alpha</math>qR</i>	GAGAAGATGATCTGAGTGTG
<i>IL-6qF</i>	GACCTGTCTATACCACTTCAC
<i>IL-6qR</i>	GCCATTGCACAACCTCTTTTC
<i>lspApF</i>	TTATTCTAGGTGGTGGCATTGG
<i>lspAqR</i>	TTCGTTTTGCGGTGCTCTAC

---

Primers used for EMSA

<i>inIAEF</i>	GGCTCCGTAGACAGATTAGC
<i>inIAER</i>	ACTTTTCAACCATAACATATCG
<i>Imo1100EF</i>	CATTTACTTACCTTAAGACAAG
<i>Imo1100ER</i>	CGTACAAGACATACCGTCTAC
<i>Imo1101EF</i>	ATAATCTGATATTATGTATTTG
<i>Imo1101ER</i>	CAAATACATAATATCAGATTAT
<i>Imo1102EF</i>	AGCTTTCTTCTTTTGCTCGC
<i>Imo1102ER</i>	GAACCTTTTCCTCATCAAAAC

Primers used for ChIP-qPCR

<i>cadCChIPF</i>	TCCTAAACACTCCTTTTCAA
<i>cadCChIPR</i>	TCTTTTGCTCGCATAATAGT
<i>cadAChIPF</i>	GCACAATTCGTACAAGAC
<i>cadAChIPR</i>	TCAAACAAACACTTGAATGT
<i>lspBChIPF</i>	CATTCAAGCGTTTGTTTG
<i>lspBChIPR</i>	CTTCATTTAACGTCTCCTTT
<i>inIABChIPF</i>	CAATTCGTGGGGAGCATA
<i>inIABChIPR</i>	TCAGGTTTCGTTGTATAGGA

---

**Table S2 – *Lm* gene expression fold change during mouse infection**

Gene name	Gene code	Fold change (spleen/BHI 37°C)*
<i>lspB</i>	<i>Imo1101</i>	-3,3
<i>cadC</i>	<i>Imo1102</i>	9,7
<i>lspA</i>	<i>Imo1844</i>	-3,3
<i>lgt</i>	<i>Imo2482</i>	-2,3

\* Data from Camejo *et al*, PLoS Pathog. 2009; 5(5):e1000449

**Table S3**

**Protein name:** LpeA (310 aa)    ***Imo:*** *Imo1847*    **Mass:** 34453    **Score:** 116    **Expect:** 7.2x10<sup>-9</sup>    **Matches:** 29


Peptide	Position
KTDGKLNVVATYSILADIVK	28 - 47
TDGKLNVVATYSILADIVK	29 - 47
LNVVATYSILADIVK	33 - 47
YLTEKGK	127 - 133
YLTEKGKTSETDPHAWLDLHNGIYTENVR	127 - 156
GKTSETDPHAWLDLHNGIYTENVR	132 - 156
GKTSETDPHAWLDLHNGIYTENVRDALVK	132 - 161
TSETDPHAWLDLHNGIYTENVR	134 - 156

TSETDPHAWLDLHNGIYTENVRDALVK	134 - 161
YIDKLATLDKEAK	177 - 189
QKFADLPENQK	190 - 200
FADLPENQK	192 - 200
FADLPENQKTLVTSEGAFK	192 - 210
FADLPENQKTLVTSEGAFKYFAAR	192 - 215
TLVTSEGAFKYFAAR	201 - 215
AAIWEINTESQGTPDQMK	220 - 238
AAIWEINTESQGTPDQMKQIVGIVEKEK	220 - 248
QIVGIVEKEKVPNLFVETSVDPR	239 - 261
EKVPNLFVETSVDPR	247 - 261
VPNLFVETSVDPR	249 - 261
SMESVSKETGVPIFAK	262 - 277
SMESVSKETGVPIFAK	262 - 277
ETGVPIFAK	269 - 277
IFTDSTAK	278 - 285
IFTDSTAKKGEVGDTYLEMMR	278 - 298
IFTDSTAKKGEVGDTYLEMMR	278 - 298
KGEVGDTYLEMMR	286 - 298
GEVGDTYLEMMR	287 - 298
YNLDKIHDGLAK	299 - 310

Coverage: 185/310 aa = 59,7 %

MKKIIVVSLFALVVVLGCSSQNSDSKKT**TDGKLNVVATYSILADIVKNVGGN**KIELHSIVPVGVDPHEYDPLPANIQSAADADLIFYN  
TADKSREDKNQVVLSKGVKPKYL**TEKGKTSETDPHAWLDLHNGIYTENVRDALVK**ADPDNADFYKENAKKYIDKLATLDKEAK  
**GAFKYFAARYGLKAAIWEINTESQGTPDQMKQIVGIVEKEKVPNLFVETSVDPRSMESVSKETGVPIFAKIFTDSTAKKGEVG**

548








Figure 2


A



B



C



D




Figure 3








Figure 4

A



B



C




Figure 5






Figure 6

A      Amino acid identity between CadC and CadA proteins from several organisms

Species	Strain	Location	Identity with CadC/CadA
<i>S. aureus</i>	RN4220	Plasmid pI258	48%/67%
<i>S. thermophilus</i>	4134	Chromosome	90%/95%
<i>L. monocytogenes</i>	Lm74	Plasmid Lm74	58%/70%
<i>L. innocua</i>	CLIP 11262	Plasmid	52%/73%






Figure S1





Figure S2

A



B




Figure S3